What top creators are saying about United Therapeutics Corporation(UTHR)

Mentioned as the opposing party in the patent dispute associated with the tentative Liquidia identification; no standalone investment view was provided.

Involved in a court stipulation with Liquidia, but the sealed filing's terms and implications were not known.

Mentioned alongside Liquidia in connection with proposed resolutions, with no investment thesis discussed.

Discussed in connection with a legal matter involving Liquidia; the sealed stipulation's terms and implications were unclear.

Involved in an ongoing legal dispute with Liquidia, with a court docket update expected to include proposed remedies; no ruling or price target was provided.

Involved in ongoing patent litigation with Liquidia; the transcript provided no prediction of the court outcome or financial impact.

Won the court case against Liquidia concerning the ILD patent. Speakers expected UTHR to benefit relative to Liquidia and mentioned it as a possible hedge, but gave no price target or detailed valuation.

Won a court case against Liquidia over a patent related to ILD use of Liquidia's drug. The speakers discussed UTHR as a possible hedge but gave no firm recommendation or target.

Aggressively scaling organ manufacturing with FDA trials for Xenokidney and XenoHeart, opening commercial-scale facilities, and expanding into thymic rejuvenation and autologous organs for long-term growth

Offers strong exposure to high-barrier synthetic biology and organ manufacturing markets with upcoming catalysts including commercial facility expansions and clinical trials for xenotransplantation and autologous organ engineering.

Partnering with Varda Space to manufacture pharmaceuticals in microgravity for improved protein crystallization.

Investing heavily in xenografts (pig-grown organs), which could disrupt the organ transplant market.

The speaker has been bearish on the stock but admits it was a poor decision because the company has been 'really good at executing,' highlighting the risk of shorting well-run companies.

The speaker describes it as a 'weird company' and wonders when its 'miracle run will end' because its drugs have no patent life left. This makes its long-term cash flow questionable and could make it a 'good short'.